ArticleThe British journal of ophthalmology2022

Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study.

Louisa Maria Bulirsch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.